COVID-19 and rheumatology: is shielding really necessary?

Br J Hosp Med (Lond)

Department of Rheumatology and General Medicine, Barnet Hospital, Royal Free London NHS Foundation Trust, London, UK.

Published: June 2020

Rheumatology patients who are taking immunosuppressants are considered to be at 'high risk' from COVID-19, hence have been self-isolating or shielding. However, they may be protected from the features of hyperinflammation driven by a 'cytokine storm', so may have better clinical outcomes if infected. This editorial discusses whether it may not be necessary to advise these patients to shield.

Download full-text PDF

Source
http://dx.doi.org/10.12968/hmed.2020.0284DOI Listing

Publication Analysis

Top Keywords

covid-19 rheumatology
4
rheumatology shielding
4
shielding necessary?
4
necessary? rheumatology
4
rheumatology patients
4
patients immunosuppressants
4
immunosuppressants considered
4
considered 'high
4
'high risk'
4
risk' covid-19
4

Similar Publications

Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.

View Article and Find Full Text PDF

SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.

Front Immunol

January 2025

Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.

Introduction: Multiple myeloma (MM) is an uncontrolled plasma cell proliferation in the bone marrow, leading to immune dysregulation with impaired humoral immune responses. Conversely, cellular-based responses play a vital role in MM patients. However, the extent and duration of cellular-induced protection remain unclear to date.

View Article and Find Full Text PDF

Introduction: Upon infection, T cell-driven B cell responses in GC reactions induce memory B cells and antibody-secreting cells that secrete protective antibodies. How formation of specifically long-lived plasma cells is regulated via the interplay between specific B and CD4+ T cells is not well understood. Generally, antibody levels decline over time after clearance of the primary infection.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with rheumatic diseases tend to recover from COVID-19 faster (average 13 days) compared to their family members (average 16 days), despite being on immunosuppressive treatments.
  • The study found that rheumatic patients have a lower risk of developing moderate to severe COVID-19, with pre-infection use of NSAIDs linked to a higher chance of mild cases.
  • Patients using disease-modifying anti-rheumatic drugs (DMARDs) before infection were significantly less likely to develop severe cases compared to those who were not on these medications.
View Article and Find Full Text PDF

The survival of B cells is compromised in kidney disease.

Nat Commun

December 2024

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Antibody-mediated protection against pathogens is crucial to a healthy life. However, the recent SARS-CoV-2 pandemic has shown that pre-existing comorbid conditions including kidney disease account for compromised humoral immunity to infections. Individuals with kidney disease are not only susceptible to infections but also exhibit poor vaccine-induced antibody response.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!